Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

Affiliations

¹ Division of Gastroenterology and Hepatology, University of California Davis Health, Sacramento, California, USA.
² Hôpital Saint-Antoine, Paris, France.
³ Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
⁴ Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
⁵ Division of Gastroenterology, University of Colorado, Aurora, Colorado, USA.
⁶ Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
⁷ New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
⁸ Vagelos College of Physician and Surgeons, Columbia University, New York, New York, USA.
⁹ Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
¹⁰ Division of Hematology and Oncology Tucson, University of Arizona, Arizona, USA.
¹¹ David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
¹² Yale School of Medicine, New Haven, Connecticut, USA.

Comment

Christopher L Bowlus et al. Hepatology. 2023.

. 2023 Jun 1;77(6):E176-E177.

doi: 10.1097/HEP.0000000000000305. Epub 2023 Jan 26.

¹ Division of Gastroenterology and Hepatology, University of California Davis Health, Sacramento, California, USA.
² Hôpital Saint-Antoine, Paris, France.
³ Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
⁴ Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
⁵ Division of Gastroenterology, University of Colorado, Aurora, Colorado, USA.
⁶ Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
⁷ New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
⁸ Vagelos College of Physician and Surgeons, Columbia University, New York, New York, USA.
⁹ Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
¹⁰ Division of Hematology and Oncology Tucson, University of Arizona, Arizona, USA.
¹¹ David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
¹² Yale School of Medicine, New Haven, Connecticut, USA.

No abstract available

Comment on

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.
Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. Bowlus CL, et al. Hepatology. 2023 Feb 1;77(2):659-702. doi: 10.1002/hep.32771. Epub 2022 Oct 20. Hepatology. 2023. PMID: 36083140 No abstract available.
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
Ali AH, Buness CW, Fischer R, Holtmann GJ, Shah A, Lewindon P, Shah S, Ragnekar AS, Taylor AE, Goel A, Cox KL, Alrabadi L, Wadsworth S, Kulkarni SS, Lindor KD. Ali AH, et al. Hepatology. 2023 Jun 1;77(6):E174-E175. doi: 10.1097/HEP.0000000000000304. Epub 2023 Jan 30. Hepatology. 2023. PMID: 36705026 No abstract available.

1. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77:761–806.
1. Shah A, Crawford D, Burger D, Martin N, Walker M, Talley NJ, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis. 2019;39:432–41.
1. Ali AH, Damman J, Shah SB, Davies Y, Hurwitz M, Stephen M, et al. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020;55:941–50.
1. Deneau MR, Mack C, Mogul D, Perito ER, Valentino PL, Amir AZ, et al. Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis. Hepatology. 2021;73:1061–73.